Disease | colorectal cancer |
Phenotype | C0019348|herpes simplex |
Sentences | 1 |
PubMedID- 20486770 | This multicenter phase i/ii study evaluated the safety, pharmacokinetics, and antitumor effects of repeated doses of nv1020, a genetically engineered oncolytic herpes simplex virus, in patients with advanced metastatic colorectal cancer (mcrc). |
Page: 1